Phase 3 N=64 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
HIV Infections · CMV Cytomegalovirus Retinitis
Primary: Survival — 6; 7; 3; 20 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=279 Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
HIV Infections · Acquired Immunodeficiency Syndrome · Cytomegalovirus Retinitis
Primary: Morbidity — 88; 93; 93 participants
Phase 3 N=61 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
Cytomegalovirus Retinitis · HIV Infections
Primary: Survival — 31; 30 participants
Phase 3 N=209 Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)
HIV Infections · Cytomegalovirus Retinitis
Primary: Mortality Rate — 0.68; 0.31 deaths per person-year
Phase 3 N=234 Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
HIV Infections · Cytomegalovirus Retinitis
Primary: Mortality — 107; 127 participants
Phase 2 N=40 Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
Kaposi Sarcoma · Human Immunodeficiency Virus · Immune Reconstitution Syndrome
Primary: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) — 0; 3 Participants
Phase 4 N=40 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
Phase 4 N=30 Valganciclovir to Reduce T Cell Activation in HIV Infection
HIV Infections · Cytomegalovirus Infections
Primary: Change in %CD38+ Human Leukocyte Antigen-D-related (HLA-DR)+ CD8+ T Cells From Baseline to Week 8. — 1.3; -4.0 percentage of activated T cells
Phase 3 N=399 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Congenital Cytomegalovirus Infection · Maternal Cytomegalovirus Infection
Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42
Phase 3 N=326 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Cytomegalovirus Infections
Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002
N/A N=14 An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients
Cytomegalovirus Infections
Primary: Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis — 3 participants
Phase 2 N=10 Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Cytomegalovirus Infections
Primary: Virological Response on Treatment Week 6 — 5 Participants
Phase 3 N=452 A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
CMV
Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant — 155; 78 Participants
Phase 2 N=35 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
Cytomegalovirus Infection
Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859
Phase 3 N=96 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Cytomegalovirus Infection
Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants
Phase 3 N=299 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Cytomegalovirus Infections
Primary: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months — 14.1; 42.6 percentage of participants
Phase 2 N=61 Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Leukemia · Lymphoma
Primary: Number of Participants With Adverse Events — 1; 31; 1; 22 Participants
N/A N=878 Pre-engraftment Cytomegalovirus DNAemia
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 2 N=168 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
Phase 2 N=1 Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
Leukemia · Lymphoma
Primary: Number of Participants With Non-Relapse Mortality — 0 Participants
Phase 2 N=160 Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
Acute Lung Injury · Acute Respiratory Distress Syndrome · Respiratory Failure
Primary: Serum IL-6 Level — -0.79; -0.79 pg/mL
Phase 2 N=131 Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients
HCMV Reactivation or HCMV End-Organ Disease
Primary: Number of Participants With "HCMV Prophylaxis Failure" — 16; 10; 10; 21 Participants — p=0.007
Phase 2 N=33 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
Phase 4 N=205 CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
Cytomegalovirus Infection
Primary: Incidence of Cytomegalovirus (CMV) Disease. — 9; 20 participants — p=0.0396
Phase 2 N=239 Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
Cytomegalovirus Infection
Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants
Phase 2 N=44 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…
Phase 2 N=137 ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Transplantation Infection · Epstein-Barr Virus Infections · Cytomegalovirus Infections
Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants
Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Phase 2 N=57 Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
Macular Degeneration
Primary: Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR…